Publisher
Springer Science and Business Media LLC
Subject
Drug Discovery,Pharmaceutical Science,Agronomy and Crop Science,Ecology,Aquatic Science,General Medicine,Ecology, Evolution, Behavior and Systematics
Reference46 articles.
1. CFR 21 Part 211 Current good manufacturing practice for finished pharmaceuticals. Office of the Federal Register. National Archives and Records Administration. 2020. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=211. Accessed 6 Oct 2021.
2. EU GMP Annex 1 Revision: manufacture of sterile medicinal products (draft). European Commission. 2020. https://www.gmp-compliance.org/files/guidemgr/2020_annex1ps_sterile_medicinal_products_en.pdf. Accessed 6 Oct 2021.
3. General Chapter: USP. <790> Visible particulates in injections. In: USP-NF. Rockville, MD: USP; May 1, 2016. https://doi.org/10.31003/USPNF_M7197_01_01
4. Jiskoot W, Randolph TW, Volkin DB, Middaugh CR, Schöneich C, Winter G, et al. Protein instability and immunogenicity: roadblocks to clinical application of injectable protein delivery systems for sustained release. J Pharm Sci. 2012;101(3):946–54. https://doi.org/10.1002/jps.23018.
5. Jiskoot W, Kijanka G, Randolph TW, Carpenter JF, Koulov AV, Mahler HC, et al. Mouse models for assessing protein immunogenicity: lessons and challenges. J Pharm Sci. 2016;105(5):1567–75.
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献